Planned date of completion: End of September 2011Note: Shares of Nycomed US Inc., which focuses on specialty pharmaceuticals in dermatology, are excluded from the share purchase agreement.3. About Nycomed(1)
Corporate name: Nycomed A/S(2)
Headquarters: Zurich, Switzerland(3)
Representative: Hakan Bjorklund (CEO)(4)
Established: 2005 (Operation started in 1874)(5)
Capital stock: 98,836 Euro(6)
Shares: non-listed ordinary shares(7)
Fiscal year: End of December (8)
No. of employees: approximately 12,500 (including Nycomed US)(9)
Relationship with Takeda: no matters to report regarding capital, personal and transactional relationship with Takeda(10)
Financial performance of the Nycomed Group for the recent two yearsincluding Nycomed U.S. (unit: million Euro)Fiscal year 2010
Fiscal year 2009Net turnover
3,228.0Gross profit Margin
232.7EBITDA after adjustment(*)
1,539(*) After adjustment of the difference such as those derived from evaluation of
inventories in accordance with "Accounting Standard for Business Combinations"
EBITDA: earnings before interest, taxes, depreciation, and amortizationTakeda will announce the financial impact which this transaction will have on its consolidated financial statements of its fiscal year 2011 together with the revised financial outlook of the year.
Takeda Media and Investor Contacts:
For Japanese Media and Global IR Inquiries:
|SOURCE Takeda Pharmaceutical Company Limited|
Copyright©2010 PR Newswire.
All rights reserved